EG23951A - Cilostazol preparation - Google Patents
Cilostazol preparationInfo
- Publication number
- EG23951A EG23951A EG20000310A EG20000310A EG23951A EG 23951 A EG23951 A EG 23951A EG 20000310 A EG20000310 A EG 20000310A EG 20000310 A EG20000310 A EG 20000310A EG 23951 A EG23951 A EG 23951A
- Authority
- EG
- Egypt
- Prior art keywords
- cilostazol preparation
- cilostazol
- preparation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP8136399 | 1999-03-25 | ||
JP27914799 | 1999-09-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
EG23951A true EG23951A (en) | 2008-01-29 |
Family
ID=26422384
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EG20000310A EG23951A (en) | 1999-03-25 | 2000-03-11 | Cilostazol preparation |
Country Status (15)
Country | Link |
---|---|
US (1) | US7144585B1 (xx) |
EP (1) | EP1162973B1 (xx) |
JP (1) | JP2011063611A (xx) |
AR (1) | AR022974A1 (xx) |
AT (1) | ATE296100T1 (xx) |
AU (1) | AU781881B2 (xx) |
CA (1) | CA2368626C (xx) |
DE (1) | DE60020343T2 (xx) |
EG (1) | EG23951A (xx) |
ES (1) | ES2238994T3 (xx) |
HK (1) | HK1041649B (xx) |
MY (1) | MY131255A (xx) |
PT (1) | PT1162973E (xx) |
TW (1) | TWI263507B (xx) |
WO (1) | WO2000057881A1 (xx) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2006343445B8 (en) * | 1998-11-02 | 2011-06-16 | Elan Pharma International Limited | Nanoparticulate and controlled release compositions comprising a platelet aggregation inhibitor |
US20030045547A1 (en) | 2001-05-02 | 2003-03-06 | Shinji Aki | Process for producing carbostyril derivatives |
PT1300160E (pt) * | 2000-05-24 | 2014-05-02 | Otsuka Pharma Co Ltd | Processo para estabilizar uma preparação |
GB0107106D0 (en) * | 2001-03-21 | 2001-05-09 | Boehringer Ingelheim Pharma | Powder inhaler formulations |
US7399864B2 (en) | 2001-05-02 | 2008-07-15 | Otsuka Pharmaceutical Co., Ltd. | Process for producing carbostyril derivatives |
US20050101631A1 (en) | 2002-08-01 | 2005-05-12 | Otsuka Pharmaceuticals Company | Process for producing carbostyril derivatives |
ATE395044T1 (de) | 2002-02-01 | 2008-05-15 | Pfizer Prod Inc | Pharmazeutische zusammensetzungen amorpher dispersionen von wirkstoffen und lipophiler mikrophasenbildender materialien |
AU2003230189A1 (en) * | 2003-01-29 | 2004-08-23 | Nitin Bhalachandra Dharmadhikari | Oral controlled release pharmaceutical composition containing metaxalone as active agent |
JP2007501218A (ja) | 2003-08-04 | 2007-01-25 | ファイザー・プロダクツ・インク | 非晶質薬物の吸着物および親油性ミクロ相形成物質の医薬組成物 |
WO2005023225A1 (en) * | 2003-09-05 | 2005-03-17 | Ranbaxy Laboratories Limited | Cilostazol adsorbate |
TWI338583B (en) * | 2004-05-20 | 2011-03-11 | Otsuka Pharma Co Ltd | Solid pharmaceutical formulation |
GB0418791D0 (en) | 2004-08-23 | 2004-09-22 | Glaxo Group Ltd | Novel process |
US8506934B2 (en) | 2005-04-29 | 2013-08-13 | Robert I. Henkin | Methods for detection of biological substances |
KR100667367B1 (ko) * | 2005-05-10 | 2007-01-10 | 충남대학교산학협력단 | 용해도가 개선된 실로스타졸 복합체 조성물 및 그 제조방법 |
BRPI0609982A2 (pt) * | 2005-05-23 | 2010-05-18 | Elan Pharma Int Ltd | composição nanoparticulada estável, método para preparar uma composição nanoparticulada, uso de uma composição, e, composição de liberação controlada |
TWI383809B (zh) * | 2005-06-29 | 2013-02-01 | Otsuka Pharma Co Ltd | 含有西洛他唑(cilostazol)之口腔崩解粉末 |
RU2443406C2 (ru) * | 2005-12-22 | 2012-02-27 | Оцука Фармасьютикал Ко., Лтд. | Способ получения содержащих лекарственное вещество восковых матричных частиц, экструдер для применения в способе и лекарственное средство с замедленным высвобождением, содержащее цилостазол |
US20070196399A1 (en) * | 2006-02-21 | 2007-08-23 | Shin-Etsu Chemical Co., Ltd. | Enteric-coated preparation covered with enteric coating material for site-specific delivery of drug to site within the small intestine |
US8343548B2 (en) | 2006-08-08 | 2013-01-01 | Shin-Etsu Chemical Co., Ltd. | Solid dosage form comprising solid dispersion |
US8519120B2 (en) | 2006-08-08 | 2013-08-27 | Shin-Etsu Chemical Co., Ltd. | Methods for producing a low-substituted hydroxypropylcellulose powder |
US8343547B2 (en) | 2006-08-08 | 2013-01-01 | Shin-Etsu Chemical Co., Ltd. | Solid dosage form comprising solid dispersion |
US20080075785A1 (en) * | 2006-09-22 | 2008-03-27 | San-Laung Chow | Controlled release hydrogel formulation |
US20110165236A1 (en) * | 2006-09-22 | 2011-07-07 | Biokey, Inc. | Controlled release hydrogel formulation |
WO2008095136A2 (en) | 2007-01-31 | 2008-08-07 | Henkin Robert I | Methods for detection of biological substances |
KR20080076382A (ko) * | 2007-02-15 | 2008-08-20 | (주)아모레퍼시픽 | 실로스타졸의 제어방출 제제 및 그 제조방법 |
KR20080076440A (ko) * | 2007-02-16 | 2008-08-20 | (주)아모레퍼시픽 | 실로스타졸의 제어방출 제제 및 그 제조방법 |
EP2152689B1 (en) | 2007-04-25 | 2013-01-02 | Concert Pharmaceuticals Inc. | Analogues of cilostazol |
AR071706A1 (es) * | 2008-05-15 | 2010-07-07 | Otsuka Pharma Co Ltd | Una formulacion farmaceutica de cilostazol solida de liberacion sostenida y metodo de preparacion. |
US8580801B2 (en) * | 2008-07-23 | 2013-11-12 | Robert I. Henkin | Phosphodiesterase inhibitor treatment |
WO2011037281A1 (ko) | 2009-09-23 | 2011-03-31 | 한국유나이티드제약 주식회사 | 용출률 향상과 부작용 발현이 최소화된 실로스타졸 서방정 |
EP2570120B1 (en) * | 2010-06-08 | 2017-10-25 | Kobe Gakuin Educational Foundation | Coated particle and method for producing coated particle |
MX339452B (es) | 2010-06-16 | 2016-05-27 | Teijin Pharma Ltd | Tableta con nucleo recubierto de liberacion controlada. |
KR20130106456A (ko) * | 2011-04-29 | 2013-09-30 | 한국유나이티드제약 주식회사 | 약물 방출제어용 조성물 |
ES2422657B1 (es) * | 2012-02-10 | 2014-06-11 | Laboratorios Normon S.A. | Composición farmacéutica sólida de cilostazol |
TWI615157B (zh) | 2013-02-06 | 2018-02-21 | 大塚製藥股份有限公司 | 包括不定形西洛他唑的固體分散劑 |
US10598672B2 (en) | 2014-02-18 | 2020-03-24 | Cyrano Therapeutics, Inc. | Methods and compositions for diagnosing and treating loss and/or distortion of taste or smell |
KR101748215B1 (ko) * | 2015-05-29 | 2017-06-20 | 한국유나이티드제약 주식회사 | 경구용 서방성 제제 |
EP3409294A1 (en) | 2017-06-01 | 2018-12-05 | Przedsiebiorstwo Farmaceutyczne Lek-Am Sp Z O. O. | Tablets containing cilostazol of specific particle size distribution |
CN114533690B (zh) * | 2022-03-22 | 2023-03-21 | 许昌市中心医院 | 含抗凝血药物西洛他唑的新制剂及其制备方法 |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4344934A (en) | 1978-11-20 | 1982-08-17 | American Home Products Corporation | Therapeutic compositions with enhanced bioavailability |
DE3433239A1 (de) * | 1984-09-11 | 1986-03-20 | Bayer Ag, 5090 Leverkusen | Feste arzneizubereitung enthaltend nitrendipin und verfahren zu ihrer herstellung |
EP0179583A1 (en) | 1984-10-04 | 1986-04-30 | Merck & Co. Inc. | A system for enhancing the water dissolution rate and solubility of poorly soluble drugs |
US5624683A (en) | 1986-08-06 | 1997-04-29 | Eisai Co., Ltd. | Sustained-release multi-granule tablet |
JPS63112519A (ja) * | 1986-10-28 | 1988-05-17 | Shin Etsu Chem Co Ltd | ニフエジピン製剤の製造方法 |
DE3720757A1 (de) | 1987-06-24 | 1989-01-05 | Bayer Ag | Dhp-manteltablette |
FR2627696B1 (fr) | 1988-02-26 | 1991-09-13 | Fournier Innovation Synergie | Nouvelle forme galenique du fenofibrate |
JP2764274B2 (ja) * | 1988-03-28 | 1998-06-11 | 株式会社ミドリ十字 | 医薬組成物 |
JP2871776B2 (ja) * | 1989-03-28 | 1999-03-17 | カロライナ メディカル プロダクツ インコーポレイテッド | スピロノラクトン組成物 |
JP2642486B2 (ja) * | 1989-08-04 | 1997-08-20 | 田辺製薬株式会社 | 難溶性薬物の超微粒子化法 |
US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
FI93924C (fi) | 1991-09-17 | 1995-06-26 | Martti Lauri Antero Marvola | Menetelmä säädellysti lääkeainetta vapauttavan valmisteen valmistamiseksi |
WO1993005770A1 (en) | 1991-09-20 | 1993-04-01 | Fujisawa Pharmaceutical Co., Ltd. | Long-acting preparation |
RU2121830C1 (ru) | 1992-09-18 | 1998-11-20 | Яманоути Фармасьютикал Ко., ЛТД | Гидрогелевый препарат с длительным высвобождением лекарства |
JP3681185B2 (ja) * | 1994-03-31 | 2005-08-10 | 太田製薬株式会社 | 錠剤製造用ニフェジピン固体粒子組成物 |
JPH07291869A (ja) | 1994-04-26 | 1995-11-07 | Otsuka Pharmaceut Factory Inc | 経口投与用製剤 |
CN1128497A (zh) * | 1994-05-17 | 1996-08-07 | 株式会社大塚制药工场 | 在血液的体外循环中防止血液凝固的方法及所应用的抗血栓性药物释放装置 |
JPH0873354A (ja) * | 1994-09-07 | 1996-03-19 | Otsuka Pharmaceut Co Ltd | 気道過敏症および/または気道障害の予防、治療剤 |
US6117455A (en) * | 1994-09-30 | 2000-09-12 | Takeda Chemical Industries, Ltd. | Sustained-release microcapsule of amorphous water-soluble pharmaceutical active agent |
EP0794778A1 (en) | 1995-01-10 | 1997-09-17 | Otsuka Pharmaceutical Co., Ltd. | Resin particle, medical material and pharmaceutical preparation containing said resin particle |
JP3799093B2 (ja) * | 1995-01-10 | 2006-07-19 | 大塚製薬株式会社 | 樹脂粒状物およびこれを含有する医療製剤 |
CA2213638C (en) * | 1995-02-24 | 2004-05-04 | Nanosystems L.L.C. | Aerosols containing nanoparticle dispersions |
AUPN651895A0 (en) * | 1995-11-10 | 1995-12-07 | Down Hole Technologies Pty Ltd | Spear head assembly |
JPH1067657A (ja) | 1996-06-18 | 1998-03-10 | Otsuka Pharmaceut Co Ltd | マルチプルユニット型持続性製剤 |
WO1997048382A2 (en) * | 1996-06-18 | 1997-12-24 | Otsuka Pharmaceutical Co., Ltd. | Multiple-unit type prolonged action drug preparation |
JPH1077234A (ja) * | 1996-09-05 | 1998-03-24 | Ohara Yakuhin Kogyo Kk | 経口用固形製剤及びその製造方法 |
FR2758459B1 (fr) * | 1997-01-17 | 1999-05-07 | Pharma Pass | Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation |
FR2758461A1 (fr) | 1997-01-17 | 1998-07-24 | Pharma Pass | Composition pharmaceutique presentant une biodisponibilite elevee et son procede de preparation |
US6294192B1 (en) * | 1999-02-26 | 2001-09-25 | Lipocine, Inc. | Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents |
JP4748839B2 (ja) * | 1999-03-25 | 2011-08-17 | 大塚製薬株式会社 | シロスタゾール製剤 |
US6825214B2 (en) * | 2000-08-14 | 2004-11-30 | Teva Pharmaceutical Industries, Ltd. | Substantially pure cilostazol and processes for making same |
US20050255155A1 (en) * | 2004-05-11 | 2005-11-17 | Glenmark Pharmaceuticals Limited | Modified release cilostazol compositions |
-
2000
- 2000-03-11 EG EG20000310A patent/EG23951A/xx active
- 2000-03-17 AR ARP000101208A patent/AR022974A1/es unknown
- 2000-03-20 MY MYPI20001097A patent/MY131255A/en unknown
- 2000-03-21 AU AU31965/00A patent/AU781881B2/en not_active Ceased
- 2000-03-21 AT AT00909776T patent/ATE296100T1/de active
- 2000-03-21 US US09/555,026 patent/US7144585B1/en not_active Expired - Fee Related
- 2000-03-21 CA CA2368626A patent/CA2368626C/en not_active Expired - Fee Related
- 2000-03-21 ES ES00909776T patent/ES2238994T3/es not_active Expired - Lifetime
- 2000-03-21 WO PCT/JP2000/001722 patent/WO2000057881A1/en active IP Right Grant
- 2000-03-21 EP EP00909776A patent/EP1162973B1/en not_active Expired - Lifetime
- 2000-03-21 PT PT00909776T patent/PT1162973E/pt unknown
- 2000-03-21 DE DE60020343T patent/DE60020343T2/de not_active Expired - Lifetime
- 2000-03-24 TW TW089105430A patent/TWI263507B/zh not_active IP Right Cessation
-
2002
- 2002-05-06 HK HK02103425.7A patent/HK1041649B/zh active IP Right Revival
-
2010
- 2010-11-19 JP JP2010258873A patent/JP2011063611A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
EP1162973B1 (en) | 2005-05-25 |
DE60020343T2 (de) | 2006-01-26 |
WO2000057881A1 (en) | 2000-10-05 |
US7144585B1 (en) | 2006-12-05 |
AR022974A1 (es) | 2002-09-04 |
CA2368626A1 (en) | 2000-10-05 |
HK1041649A1 (en) | 2002-07-19 |
JP2011063611A (ja) | 2011-03-31 |
TWI263507B (en) | 2006-10-11 |
EP1162973A1 (en) | 2001-12-19 |
CA2368626C (en) | 2010-02-16 |
AU3196500A (en) | 2000-10-16 |
AU781881B2 (en) | 2005-06-16 |
HK1041649B (zh) | 2005-11-04 |
PT1162973E (pt) | 2005-08-31 |
ATE296100T1 (de) | 2005-06-15 |
ES2238994T3 (es) | 2005-09-16 |
MY131255A (en) | 2007-07-31 |
DE60020343D1 (de) | 2005-06-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EG23951A (en) | Cilostazol preparation | |
DE60033307D1 (en) | Heteroalkylamino-substituierte bicyclische stickstoffheterocyclen | |
DE50002490D1 (en) | Polyester-polyetherblockcopolymere | |
PL357601A1 (en) | 4-pyrimidinyl-n-acyl-l-phenylalanines | |
DE50002614D1 (en) | Sigma-delta-modulator | |
DE60028360D1 (en) | Ptk-chipthermistor | |
DE50000137D1 (en) | Spirofluorenopyrane | |
DE10081629D2 (en) | Seilzugbefestigung | |
DE60012950D1 (en) | Polyacetalharzzusammensetzung | |
GB2352957B (en) | Numnah | |
HK1046280B (zh) | 1-三氟甲基-4-羥基-7-哌啶基-氨甲基苯並二氫吡喃衍生物 | |
GB9913742D0 (en) | Horologe improvement | |
GB9914798D0 (en) | Ensure | |
AU141428S (en) | Turnpiece | |
DE50008219D1 (en) | Common-rail-injektor | |
DE60007846D1 (en) | Sterndreieckschalter | |
DE50005334D1 (en) | Tricyclische benzoylcyclohexandion-derivate | |
AU140373S (en) | Bumbag | |
TW433433U (en) | Improved lampstand | |
HK1048362A1 (zh) | 光學模塊 | |
CA85665S (en) | Blender | |
CA87158S (en) | Pendulette | |
DE50005597D1 (en) | Laryngoskop | |
TW395422U (en) | Form | |
AU143941S (en) | Blender |